We found a match
Your institution may have rights to this item. Sign in to continue.
- Title
NIH Starts Testing Nasal COVID-19 Vaccine in US.
- Authors
Harris, Emily
- Abstract
The US National Institutes of Health (NIH) has begun enrolling participants in a clinical trial to test the safety and effectiveness of a nasal COVID-19 vaccine called MPV/S-2P. The vaccine is a modified murine pneumonia virus vector with a SARS-CoV-2 spike protein. Previous research on nonhuman primates showed that the nasal vaccine was safe and induced strong immune responses in the nose and respiratory tract. This phase 1 trial is part of the NIH's Project NextGen initiative, which aims to develop new tools against COVID-19. The study will enroll 60 adults aged 18 to 64 who have already received three doses of an mRNA COVID-19 vaccine.
- Subjects
COVID-19 vaccines; MESSENGER RNA; VACCINE effectiveness; COMMUNICABLE diseases; COVID-19 testing
- Publication
JAMA: Journal of the American Medical Association, 2024, Vol 332, Issue 8, p610
- ISSN
0098-7484
- Publication type
Article
- DOI
10.1001/jama.2024.13769